for people ages 18 years and up (full criteria)
at Fresno, California and other locations
study started
estimated completion



This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation


Pulmonary Arterial Hypertension, PAH, Oral Treprostiinil, Orenitram, Hypertension, Treprostinil, Oral treprostinil


You can join if…

Open to people ages 18 years and up

Patients are eligible for the registry if:

1. The patient voluntarily gives informed consent to participate in the study. 2. The patient must be at least 18 years of age or older. 3. The patient is prescribed Orenitram (per the package insert indication), and plans to initiate therapy with this medication or has been receiving Orenitram for 182 or fewer days. 4. The patient agrees to dosing, prostacyclin-related AE of interest record keeping, survey participation during designated time periods, and recording any medication changes, use, for the duration of the study. 5. The patient has the ability to answer surveys and use the diary in English. 6. The patient must have an email address and be willing to access the PRO Portal.

You CAN'T join if...

Patients are ineligible for the registry if:

1. The patient has previously received Orenitram for more than 182 days. 2. The patient is currently participating in an investigational drug or device study or has participated in a clinical study with an investigational product other than Orenitram in PAH within


  • University of California - San Francisco
    Fresno California 94143 United States
  • Santa Barbara Pulmonary Associates
    Santa Barbara California 93105 United States


in progress, not accepting new patients
Start Date
Completion Date
United Therapeutics
Study Type
Observational [Patient Registry]
Expecting 300 study participants
Last Updated